Orexo AB
The answer first
Does Orexo beat the market?
No, Orexo has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 47% of Nordic stocks
- Quality67
- Value85
- Trend1
No. 65 of 195 in healthcare
Max for seven days
Follow Orexo with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Orexo
Your first answer is free, no account needed.
Do you own Orexo, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Orexo and a few more. Free, no card.
Super Stock+44.6%In short
- Orexo has fallen 96.3% over the past year, including dividends.
- Overall, Orexo ranks better than 47% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.0%. The price is 99.4% below its peak now.
What do analysts think of Orexo?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 47% of Nordic stocks.
No. 65 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 92 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity2.79
- Asset turnoverSales divided by everything the company owns0.03
- Return on equityProfit divided by equity−89.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 12 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.2
- P/SPrice divided by sales2.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 197 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−92.7%
- 6 months−94.9%
- 9 months−96.2%
- 12 months−96.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Orexo
5 funds we follow own Orexo. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About Orexo
Orexo AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 55 employees.
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori.


See the full analysis of Orexo.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card